ATAI Life Sciences (ATAI)

• Market cap: $1.51B
• 1 day: 17.7%
• 5 days: 23.8%
• 1 month: 39.91%
• 3 months: 131.18%
• 6 months: 338.78%
• Year to date: 303.12%
• 1 year: 437.5%
• 5 years: -66.84%
• 10 years: -66.84%
• Sector: Healthcare
• Industry: Biotechnology

About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Employees: 54